INTRODUCTION {#h0.0}
============

Sensing of and responding to environmental changes are of vital importance for microbial cells, as they facilitate their fine-tuned adaptation to prevailing conditions. The range of parameters a single cell can monitor is immense, including conditions as diverse as nutrient supply, oxygen levels, temperature, pH, cell densities, and presence of toxic compounds. It is therefore hardly surprising that bacteria have developed a plethora of sensory and regulatory strategies to accomplish this feat. In the specific context of antibiotic resistance, bacteria have to be able to accurately determine the severity of the attack in order to decide on an adequate response. The precision of this response is key to both survival of antimicrobial action and minimizing the metabolic cost of resistance ([@B1], [@B2]).

One common feature of controlling a cellular response is to monitor the ambient concentration of a specific substance. In the case of antibiotic resistance, this can be achieved, e.g., via direct binding to a sensory protein, such as the vancomycin-responsive histidine kinase (HK) VanSsc of *Streptomyces coelicolor* ([@B3]). An alternative approach is to monitor the cellular damage caused by the antibiotic, as is the case, e.g., for the LiaRS cell envelope damage-sensing system of *Bacillus subtilis* ([@B4]). Such an indirect sensing strategy allows the cell to integrate into its response its current physiological state, which can significantly influence the potency of a given concentration of antibiotic. For instance, fast-growing cells are usually much more susceptible to antibiotic action than slow-growing cells. While a damage-sensing strategy undoubtedly provides a more context-dependent response, it requires the accumulation of a certain degree of cellular damage. Here, we present evidence for a third, previously undescribed regulatory strategy, allowing the bacterium to directly monitor its current capacity to deal with the antibiotic threat by measuring the activity of a drug efflux pump (referred to as "flux sensing").

We recently showed that a unique type of ATP-binding cassette (ABC) transporters is actively involved in a signaling pathway controlling its own production ([@B5][@B6][@B7]). These transporters mediate resistance against a wide range of antimicrobial peptides in many Gram-positive species, including important pathogens, such as *Staphylococcus aureus* and *Enterococcus faecalis* ([@B8]). Their expression is regulated by two-component systems whose HKs lack discernible ligand-binding domains and instead form a sensory complex with the transporter ([@B9], [@B10]). The signaling process is best understood in *Bacillus subtilis*, where the two-component system BceRS and its associated ABC-transporter BceAB together sense and counteract the deleterious effects of bacitracin and several other antimicrobial peptides interfering with the lipid II cycle of cell wall biosynthesis, by triggering a 500-fold increase in the expression of the *bceAB* transporter operon ([@B5], [@B9], [@B11]) ([Fig. 1a](#fig1){ref-type="fig"}).

![Schematic of conceivable sensory scenarios employed by the BceRS-BceAB system. In an external sensing scenario (a), the ABC transporter BceAB might act as a scaffold that keeps the histidine kinase BceS in an active conformation, which would allow BceS to perceive the extracellular concentration of bacitracin (red symbols). Since up-regulation of BceAB is not expected to change the extracellular concentration of bacitracin, the rate of gene expression should be independent of the BceAB level in this scenario (no feedback). In an internal sensing scenario (b), BceAB might be required to translocate bacitracin into the cytoplasm where BceS could sense its abundance. Here, up-regulation of BceAB should lead to an increased rate of bacitracin influx, which would in turn lead to further up-regulation of BceAB expression (positive feedback). In a flux-sensing scenario (c), BceAB itself is the true sensor, which directly signals its transport activity to BceS. In such a scenario, up-regulation of BceAB would reduce the load experienced by each individual transporter and thereby reduce signaling via BceS (negative feedback). (d) Schematic depiction of the expected impact of different levels of the BceAB transporter (low, red curves; high, green curves) on dose-dependent P*~bceA~* activity.](mbo0041524000001){#fig1}

To characterize the regulatory role of the transporter, here we took a systems approach, combining mathematical modeling with experiments probing the time-resolved, dose-dependent response of the Bce system to its substrate bacitracin. We show that signaling within the Bce system operates by a flux-sensing mechanism, monitoring the activity of individual transporters. Our model allowed us to derive a unique response signature for a flux sensor, which was experimentally validated. Moreover, the model was able to predict the antibiotic sensitivity of cells depending on transporter expression, leading us to propose that flux sensing serves as a novel produce-to-demand strategy to control antibiotic resistance in changing environments.

RESULTS {#h1}
=======

ABC transporter production rapidly adapts to a wide range of bacitracin inputs. {#s1.1}
-------------------------------------------------------------------------------

To obtain detailed quantitative information on the regulatory dynamics of the Bce system, we first studied the relationship between the external antibiotic concentration and the transcriptional response of the target promoter P*~bceA~*. To this end, exponentially growing SGB073 cells (wild-type *B. subtilis* carrying a chromosomally integrated P*~bceA~-luxABCDE* reporter) were exposed to sublethal concentrations of bacitracin. At virtually all bacitracin concentrations tested, luciferase activity initially rose rapidly upon antibiotic addition, before leveling off to reach a plateau 20 to 30 min after induction ([Fig. 2A](#fig2){ref-type="fig"}). A plot of the plateau level against antibiotic concentration revealed that the system's response quickly adapted to a wide dynamic range of antibiotic input (0.1 to 100 µg/ml bacitracin) ([Fig. 2B](#fig2){ref-type="fig"}). Such gradual, homeostatic control of target gene expression is often found in regulatory systems that exploit negative-feedback mechanisms, while positive-feedback regulation frequently enables switch-like or even hysteretic responses ([@B12]). The presence of a negative feedback mechanism was also suggested by our observation that the P*~bceA~* promoter activity reached its steady-state value within a short time (20 to 30 min) ([Fig. 2A](#fig2){ref-type="fig"}) relative to the cell doubling time of \~70 min (see [Fig. S1](#figS1){ref-type="supplementary-material"} in the supplemental material), as negative-feedback control is known to reduce the response time of genetic circuits ([@B13]).

![Gene expression driven by the P*~bceA~* promoter rapidly adapts to a wide range of antibiotic concentrations. (A) Exponentially growing cells of strain SGB073 were exposed to sublethal concentrations of bacitracin at 0 min, and luciferase activity from a *P~bceA~*-*luxABCDE* reporter construct was monitored over time. Data are means and standard deviations for at least three independent biological replicates (lower error bars are not depicted if negative values were reached). Lines show the dynamics predicted by the quantitative mathematical model described in the main text. (B) Experimental dose-response curve of the P*~bceA~* promoter at a fixed time (42.5 min) after induction (symbols) and the fit to the mathematical model (lines). For details, see the text.](mbo0041524000002){#fig2}

To elucidate the source of this apparent feedback effect, we considered three plausible roles of the transporter in the regulatory pathway. (i) In the simplest scenario, the transporter acts as a mere ligand-binding component in a sensory complex with the HK, as is the case in regulation of sugar phosphate uptake by the Uhp system in *Escherichia coli* ([@B14], [@B15]). The input signal for such a system is the ambient concentration of the cognate substrate ([Fig. 1a](#fig1){ref-type="fig"}). This signal will not change if the number of transporters inserted in the membrane increases, since the amount of HK, and hence the number of sensory complexes, remains constant. Thus, there will be no feedback on regulation. (ii) Alternatively, the transporter might be required to translocate the substrate to a cytoplasmic recognition site ([Fig. 1b](#fig1){ref-type="fig"}). Such a strategy is realized, e.g., in the regulation of arabinose utilization by *E. coli* ([@B16]), where the level of intracellular substrate serves as the input signal. While the polarity of BceAB-mediated transport is not known, it has been suggested that BceAB may act as an importer of bacitracin, releasing it into the cytoplasm for degradation ([@B5], [@B8]). Here, the strength of the stimulus should increase during the induction process, because the amount of bacitracin transported into the cell will rise with the supply of transporters, thus creating a positive feedback on the response. (iii) The third conceivable scenario is that the HK activity is determined by the rate of flux through individual transporters ([Fig. 1c](#fig1){ref-type="fig"}). BceAB has also been proposed to act as a "hydrophobic vacuum cleaner" ([@B17]), conferring resistance by clearing the target from the inhibitory grip of the antibiotic ([Fig. 1c](#fig1){ref-type="fig"}) ([@B7], [@B18]). In such a scenario, increasing BceAB copy numbers should alleviate the load experienced by individual transporters ([Fig. 1c](#fig1){ref-type="fig"}), resulting in a negative feedback of BceAB on its own expression. Thus, qualitatively, a flux-sensing scenario best reflects the observed dynamics of P*~bceA~* activation.

The behavior of the wild-type system is compatible with a mathematical model for relative flux sensing. {#s1.2}
-------------------------------------------------------------------------------------------------------

To test if the proposed flux-sensing mechanism can quantitatively explain the regulatory dynamics in the Bce system, we developed a mathematical model, incorporating signal transduction via such a mechanism. Bacitracin is known to bind to its membrane-associated target molecule undecaprenol-pyrophosphate (UPP), thus blocking the dephosphorylation and recycling of UPP in the lipid II cycle of cell wall biosynthesis ([@B19]). If we suppose that the ABC transporter BceAB catalyzes the release of bacitracin from UPP with Michaelis-Menten enzyme kinetics, the time-dependent concentration of the bacitracin-bound form of UPP, UPP-bac, can be described by a differential equation of the form
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Here, \[bac\] is the externally applied bacitracin concentration, *k*^on^ and *k*^off^ are the spontaneous on and off rates for the binding of bacitracin to UPP, UPP~tot~ is the total UPP level in the cell, *J*~bac~ = \[UPP-bac\]/(*K~m~* + \[UPP-bac\]) is the relative bacitracin load per BceAB transporter, and *v*~max~ and *K~m~* are the maximal transport rate and Michaelis-Menten constant of BceAB, respectively (see [Tables S1 and S2](#tabS1 tabS2){ref-type="supplementary-material"} in the supplemental material).

To implement the proposed flux-sensing mechanism in our model, we took into account that the expression of the two-component system operon *bceRS* is constitutive (see [Fig. S2](#figS2){ref-type="supplementary-material"} in the supplemental material) and also that the interaction between the histidine kinase BceS and the BceAB transporter is bacitracin independent ([@B9]). Moreover, we verified that the overproduction of BceS did not significantly affect the MIC of a strain with constitutive BceAB expression (see [Fig. S3](#figS3){ref-type="supplementary-material"} in the supplemental material), indicating that the transport activity of BceAB is not affected by the formation of the sensory complex with BceS *in vivo*. Thus, as long as BceAB molecules outnumber BceS molecules, so that BceS is the limiting component in complex formation, there should be a constant number of functional BceS-BceAB sensory complexes in the cell, while the number of free BceAB transporters should change with increasing total transporter levels. Under inducing conditions this is a safe assumption, because we can readily detect the presence of BceAB, but not of BceS, using Western blotting or fluorescent protein fusions (our unpublished observations). Under noninducing conditions, both proteins are below our current detection limit and therefore not accessible to quantification. Based on the relative promoter strengths of P~*bceR*~ (see [Fig. S2](#figS2){ref-type="supplementary-material"} in the supplemental material) and P*~bceA~* ([Fig. 2A](#fig2){ref-type="fig"}), it could well be that uninduced cells possess more kinases than transporters. Nevertheless, within our mathematical model we assume that the number of sensory complexes does not change over time and thus that BceS always monitors the activity of a fixed number of transporters. While this assumption might be inaccurate in the early phase of induction, BceAB levels are expected to quickly exceed those of BceS such that the model should well reflect the experimental conditions shortly after induction.

Based on these considerations, we assume within our model that BceS signals the load of individual transporters to the response regulator BceR, such that the level of the active (phosphorylated) form of BceR is proportional to the bacitracin load per transporter, *J*~bac~. Following a thermodynamic model for transcriptional regulation ([@B20]), activation of gene expression from the P*~bceA~* promoter by phosphorylated BceR can then be formulated in terms of *J*~bac~, such that the dynamic equations for *bceAB* mRNA concentration, \[*m*\], and BceAB protein level, \[BceAB\], read
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Here, α is the basal transcription rate, ω is the ratio of maximal to basal promoter activity, λ is the mRNA degradation rate, and κ is a measure of the relative flux at which P*~bceA~* is activated. The Hill exponent (*n*) in turn reflects all forms of cooperativity in stimulus perception and signal transduction, as well as in BceR-DNA binding and recruitment of RNA polymerase. Finally, β is the translation rate and δ is the protein dilution rate due to cell doubling. The dynamic equations for luciferase reporter expression were formulated analogously to [equations 2](#eqn2){ref-type="disp-formula"} and [3](#eqn3){ref-type="disp-formula"} and are given in Materials and Methods.

We then asked whether the data in [Fig. 2](#fig2){ref-type="fig"} were in quantitative agreement with our mathematical model. To this end, all known and measured model parameters were fixed to their physiological values (see [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material), the remaining ones were confined to physiological intervals (see [Table S2](#tabS2){ref-type="supplementary-material"} in the supplemental material), and then the model was fitted to the experimental dose-response in [Fig. 2B](#fig2){ref-type="fig"} (see Materials and Methods for details of the fitting procedure). Overall, we found that the dynamic behavior of the model closely resembled the rapid adaptation kinetics observed in the experimental time series ([Fig. 2A](#fig2){ref-type="fig"}). Likewise, the model adequately captured the gradual increase of the experimental dose-response characteristics over a wide range of input levels ([Fig. 2B](#fig2){ref-type="fig"}). These findings provided the first quantitative indication that the Bce system does in fact implement a flux-sensing mechanism that monitors the bacitracin load per BceAB transporter. The agreement between theory and experiment in the early phase (0 to 15 min) after induction further demonstrates that the model assumption of a constant number of sensory complexes per cell was reasonable: if BceAB were initially less abundant than BceS, the number of sensory complexes should increase upon induction of BceAB production, which should result in a positive feedback on signaling. Such a positive feedback should cause a lag in the response while the number of sensory complexes is still very low, followed by a rapid increase in signaling as more and more complexes are formed. Such an effect is not visible in our data ([Fig. 2A](#fig2){ref-type="fig"}), showing that the window in which the number of sensory complexes is not constant is short and cannot be resolved by the luciferase reporter.

Predicting the signature of a relative flux sensor. {#s1.3}
---------------------------------------------------

One key feature of the proposed flux sensor model is that up-regulation of BceAB leads to a reduction of the bacitracin load per transporter, which ultimately down-regulates transcription of *bceAB*. Hence, if the model was correct, disabling this negative autoregulation of BceAB should abolish the graded response to bacitracin. Consequently, constitutively supplying the cell with a fixed number of transporter molecules should provide an alternative means of distinguishing between the three different signaling scenarios detailed above. For a relative flux-sensing mechanism, in cells with few transporters, the load per transporter should be saturated at low bacitracin concentrations, leading to a highly sensitive response ([Fig. 1d](#fig1){ref-type="fig"}, right). Conversely, cells with many transporters should respond more sluggishly ([Fig. 1d](#fig1){ref-type="fig"}, right), because more bacitracin is required to produce a high load per transporter. For an intracellular sensing mechanism, the opposite behavior is expected: cells with a high level of BceAB should respond more sensitively than those with few transporters, as the total amount of bacitracin translocated increases with the number of transporters present ([Fig. 1d](#fig1){ref-type="fig"}, center). Last, for an extracellular-concentration-sensing mechanism, the dose-response behavior should not be affected by alterations in the level of the transporter ([Fig. 1d](#fig1){ref-type="fig"}, left). In fact, this last situation was recently reported for the DctA/DcuS sensor complex of *E. coli* ([@B21]), in which the transporter DctA merely acts as an activity switch for the HK DcuS.

When we modified our mathematical model to accommodate constitutive production of the transporter, the predicted dose-response behavior was altered in two respects. First, the elimination of autoregulation of the level of BceAB results in a more switch-like response of the P*~bceA~* promoter to increasing bacitracin concentrations ([Fig. 3a](#fig3){ref-type="fig"}). This sharp response is due to the fact that the fit to the data for the wild type in [Fig. 2](#fig2){ref-type="fig"} yielded a Hill exponent (*n*) of 7.5 ± 0.2, suggesting that signal transduction and regulation of P*~bceA~* exhibit a high degree of cooperativity. Second, when the copy number of the transporter is changed, the model predicts a shift in the dose-response curves consistent with the signature of a flux sensor: in cells that constitutively express low levels of BceAB, the promoter is triggered by low bacitracin concentrations ([Fig. 3a](#fig3){ref-type="fig"}), while much higher concentrations of the antibiotic are required to activate P*~bceA~* in cells that synthesize large amounts of BceAB ([Fig. 3a](#fig3){ref-type="fig"}).

![Signature of a relative flux sensor. (a) Theoretical prediction of P*~bceA~-luxABCDE* dose-response curves for various levels of constitutive BceAB transporter production (colored curves), compared to the wild type with autoregulated *bceAB* expression (black curve). The expression levels of *bceAB* in the legend are percentages of the maximal P*~bceA~* expression level in the wild type. These expression levels were derived from the experimental dose-response curve of the P*~xylA~* promoter in panel b, which drives expression of *bceAB* in the experimental system in panel c. (b) Xylose-dependent dose-response curve of a P*~xylA~-luxABCDE* reporter strain (black symbols) published previously ([@B22]) and fitted by a Hill function (black curve). In addition, the EC~10~ values , i.e., concentrations at which the dose-response curves in panel c reach 10% of their maximal activity, are shown as a function of xylose concentration (red symbols). (c) Experimental P*~bceA~-luxABCDE* dose-response curves in strain SGB218, in which the endogenous chromosomal *bceAB* locus has been deleted and transporter expression is constitutively driven from a chromosomally integrated xylose-dependent P*~xylA~-bceAB* construct (colored symbols). The wild-type dose-response curve (black symbols) was derived from strain SGB073. (d) Data from panels a and c with the *x* axis rescaled by the respective EC~10~ values. For details, see the text.](mbo0041524000003){#fig3}

In order to test these predictions experimentally, we constructed a strain (SGB218) in which the endogenous *bceAB* locus had been deleted, and replaced by a chromosomally integrated construct driven by the xylose-inducible promoter P*~xylA~*. In addition, this strain carries the P*~bceA~-luxABCDE* reporter used above. We previously quantified the dose-response characteristics of P*~xylA~* ([@B22]). It showed a basal transcription level \~30-fold higher than that driven by P*~bceA~* and could be activated up to \~100-fold by increasing the xylose concentration in the medium ([Fig. 3b](#fig3){ref-type="fig"}). Based on these data, we selected five xylose concentrations (0%, 0.005%, 0.01%, 0.03%, and 0.2%) that resulted in markedly different P*~xylA~* activities. Incorporation of these promoter activities into our mathematical model led to distinct BceAB protein levels for each xylose concentration and thus also to the parameter-free predictions for the shifts in the activation threshold of P*~bceA~* discussed above ([Fig. 3a](#fig3){ref-type="fig"}).

[Figure 3c](#fig3){ref-type="fig"} shows the bacitracin-dependent P*~bceA~* activity of SGB218 cells grown in the presence of the selected xylose concentrations. Strikingly, we found that both the theoretically predicted abrupt onset of activation and the shift in induction threshold with increasing xylose concentration were quantitatively reflected in our experimental results. The latter becomes manifest, for instance, when EC~10~ values (the bacitracin concentration at which the dose-response reached 10% of its maximum) are plotted as a function of xylose concentration. Theoretically, the EC~10~ is expected to be proportional to the concentration of BceAB in the cell and, accordingly, to reflect the level of P*~xylA~* promoter activity ([Fig. 3b](#fig3){ref-type="fig"}). Indeed, the experimental EC~10~ values all fell along this curve ([Fig. 3b](#fig3){ref-type="fig"}), suggesting (i) that P*~xylA~* activity is in fact proportional to BceAB protein levels and (ii) that the number of BceAB transporters per cell determines how much bacitracin the cell will tolerate before signaling is activated. To inspect the shape of the dose-response curves in [Fig. 3c](#fig3){ref-type="fig"} more closely, we rescaled all *x* axes to the EC~10~ values. When this was done, all dose-response curves collapsed onto a single master curve ([Fig. 3d](#fig3){ref-type="fig"}). Remarkably, the experimental data points showed an even steeper increase than predicted by our model ([Fig. 3d](#fig3){ref-type="fig"}), highlighting the strong cooperativity involved in signal perception, transduction, and gene regulation at P*~bceA~*. Considering that sensory perception and signaling by the Bce system involve a multiprotein complex ([@B9]), it is not difficult to envisage such strongly cooperative effects arising. Moreover, it was previously shown that many promoters of *bceAB*-like operons contain binding sites for two dimers of the response regulator ([@B23]). Indeed, P*~bceA~* also possesses two BceR binding sites, spaced 13 bp apart and located directly upstream of the −10/−35 promoter elements. We recently showed that both binding sites are required for bacitracin-dependent induction of P*~bceA~* (C. Fang and T. Mascher, unpublished data). Since each binding site consists of a repeat sequence, each site will likely be occupied by a dimer of BceR, indicating that a total of four BceR molecules are required for promoter induction, which could further enhance cooperativity in signaling.

The model successfully predicts inhibitory concentrations of bacitracin. {#s1.4}
------------------------------------------------------------------------

Bacitracin acts by binding to the lipid carrier UPP and preventing its dephosphorylation ([@B19]). Due to its essentiality for cell growth, a certain minimal fraction of free lipid carrier is needed to maintain cell wall biosynthesis at a given growth rate, and blocking a larger fraction of UPP is thus lethal. Intuitively, expression of the BceAB transporter is expected to release UPP from the inhibitory grip of bacitracin and thereby keep a significant fraction of UPP bacitracin free. Hence, BceAB expression should directly affect the bacitracin-bound UPP levels in the cell and, with that, the cellular sensitivity to inhibition by bacitracin.

To analyze the physiological implications of the flux-sensing mechanism, we first calculated the fraction of bacitracin-bound UPP in the cell using our mathematical model. For the wild-type strain employing bacitracin-dependent feedback regulation of *bceAB* expression, the fraction of bacitracin-bound UPP first increases rapidly with the applied concentration of the antibiotic ([Fig. 4a](#fig4){ref-type="fig"}). As soon as BceS detects a significant bacitracin flux via the BceAB transporter (at ca. 0.3 µg/ml bacitracin), transporter production is up-regulated and the rate of accumulation of bacitracin-bound UPP is slowed. Based on the bacitracin concentration needed to inhibit the growth of the wild type (ca. 200 µg/ml), we calculated the lethal fraction of bacitracin-bound UPP to be 90% ([Fig. 4a](#fig4){ref-type="fig"}). In the absence of BceAB transporters, our model predicted that the fraction of bacitracin-bound UPP increases rapidly with the applied bacitracin concentration and reaches the lethal 90% threshold at 2 µg/ml bacitracin ([Fig. 4a](#fig4){ref-type="fig"}). This is slightly below the experimentally determined MIC of 8 to 16 µg/ml for a strain with *bceAB* deleted. However, the difference is not surprising given that the model does not take into account residual bacitracin resistance caused, e.g., by the UPP phosphatase BcrC and other members of the σ^M^, σ^X^, and σ^W^ regulons involved in the response of *B. subtilis* to cell envelope stress ([@B24][@B25][@B26]). In contrast to the homeostatic control seen in the wild type, for the strain with constitutive *bceAB* expression, the model predicted the binding curve to be of the same shape as in the absence of BceAB. However, the curves were shifted to ever-higher bacitracin concentrations the more transporter was present in the cell ([Fig. 4a](#fig4){ref-type="fig"}). Hence, the model also predicted that the higher the level of BceAB, the greater the antibiotic concentration required for killing ([Fig. 4a](#fig4){ref-type="fig"}).

![Inhibition of cell wall biosynthesis by blocking UPP recycling. (a) Change in the fraction of bacitracin-bound UPP as a function of external bacitracin, predicted by a model with feedback regulation (black curve) and a model with the indicated levels of constitutive *bceAB* expression (colored curves). In addition to the *bceAB* expression levels used in [Fig. 3](#fig3){ref-type="fig"}, the red curve shows the percentage of bacitracin-bound UPP in the absence of the BceAB transporter. Assuming that cell wall biosynthesis can be maintained as long as the percentage of blocked UPP carrier molecules remains below a given limit (dashed grey line), the intersection with the solid lines leads to a prediction of how the bacitracin MIC should scale with increasing BceAB expression level (dashed grey line in panel b). (b) Growth inhibition of strain SGB218 with constitutive transporter expression from a xylose-dependent P*~xylA~-bceAB* construct (colored symbols). Cultures with a low *bceAB* expression level (0% xylose) are more susceptible to bacitracin than cultures with a high *bceAB* expression level (0.2% xylose). The model quantitatively captures the scaling of this growth inhibition line (solid grey line), when background resistance mechanisms, which are reflected in an additive offset for low *bceAB* expression level, are taken into account.](mbo0041524000004){#fig4}

To confront these predictions with experimental data, we assayed the reporter strains for growth inhibition by bacitracin. For this, growth rates were determined after addition of a range of bacitracin concentrations to exponentially growing cultures producing different levels of transporter. For each culture, increasing the added concentration of bacitracin first led to a significant decrease in growth rate ([Fig. 4b](#fig4){ref-type="fig"}) and eventually to complete cessation of growth or cell lysis, with higher concentrations being required to inhibit cells expressing *bceAB* at higher levels. Prediction of the lethal threshold concentration by the model approximately reproduced the observed relationship between growth inhibition and *bceAB* expression (dashed line in [Fig. 4b](#fig4){ref-type="fig"}). The steeper decline of the theoretical curve compared to the experimental data at low levels of BceAB can again be explained by the presence of alternative resistance determinants in *B. subtilis*, as discussed above. When we adjusted the model to the background resistance of a *bceAB* deletion-containing strain (here, 15 µg/ml), it accurately described the correlation between BceAB expression levels and inhibitory bacitracin concentration (solid line in [Fig. 4b](#fig4){ref-type="fig"}).

Our model does not distinguish between the cellular concentration of UPP-bacitracin complexes (i.e., the assumed transport substrate) and the true transport flux as input parameters, because binding kinetics and transport activity are mathematically equivalent in the Michaelis-Menten equation employed. This consideration becomes important in light of the possibility that BceAB might serve as a sensor without actually translocating any of its substrate. However, if BceAB were transport deficient, the concentration of UPP-associated bacitracin should always be proportional to the extracellular antibiotic concentration, regardless of the number of functional transporters in the cell. This is entirely inconsistent with the shifts in dose-response curves observed in cells expressing different amounts of BceAB ([Fig. 3](#fig3){ref-type="fig"}). Furthermore, the good fit between observed growth inhibition by bacitracin and predicted lethal threshold at different transporter expression levels ([Fig. 4](#fig4){ref-type="fig"}) showed that the transporter indeed had an impact on the fraction of bacitracin-bound UPP and thus must be able to translocate its substrate.

Taken together, our theoretical and experimental data clearly indicate that a combination of relative flux sensing and concomitant negative feedback provides efficient homeostatic control over the level of bacitracin-bound UPP, allowing it to be maintained below the lethal concentration threshold over a range of antibiotic concentrations covering at least two orders of magnitude.

DISCUSSION {#h2}
==========

Bacteria can perceive their environment either directly, by monitoring the concentration of a relevant substance, or indirectly, by monitoring the effects on cellular physiology caused by a particular condition. We show here that sensing of transport flux of antimicrobial substances through a resistance pump presents a third and novel sensing strategy, by which the cell can directly monitor and respond to its current detoxification capacity. Through quantitative, time-resolved analysis of the dose-response dynamics, combined with mathematical modeling of the regulatory pathway, we obtained evidence that the Bce system of *B. subtilis* implements such a flux sensor, where the parameter monitored by the signaling system is the activity of individual BceAB transporters. This elegant mechanism permits continual assessment of the most critical parameter of antibiotic resistance, i.e., the cell's current capacity to deal with the inhibitory effects of the applied drug. From a systems perspective, this parameter is far more relevant to the cell than the present concentration of the antibiotic: as long as the cell's transport capacity is sufficient to detoxify the drug, there is no need for a further response even at high antibiotic concentrations. We therefore propose that flux sensing is a very cost-efficient regulatory strategy to control antibiotic resistance. To our knowledge, this is the first report of such a regulatory mechanism in any physiological context.

Over 200 Bce-like systems can currently be found in protein databases, and their components were shown to have coevolved ([@B23]). Combined with experimental confirmation of the transporter's sensory role in all systems studied to date ([@B8], [@B11], [@B27][@B28][@B29]), this tight evolutionary correlation suggests conservation of the signaling mechanism. Flux sensing may therefore be a widespread regulatory principle in antimicrobial peptide resistance. Because this mechanism relies on the intricate process of communicating transport flux between proteins, it should, conceivably, be easy to disrupt and thus might constitute a prime drug target to counteract resistance in pathogenic bacteria possessing Bce-like systems, such as *S. aureus*, *E. faecalis*, *Listeria monocytogenes*, and *Clostridium difficile* ([@B8], [@B23], [@B27], [@B30]).

Our modeling approach not only has provided evidence for a flux-sensing mechanism but also has given access to important system variables that are difficult to quantify experimentally, most notably the fraction of bacitracin-bound UPP. Analysis of such "hidden" parameters can lead to highly relevant predictions for bacterial physiology, such as our calculation of the dependence between the bacitracin concentration required to inhibit growth and the expression level of the resistance determinant. Ultimately, such an approach may have important implications for the treatment of infectious disease caused by drug-resistant bacteria. Importantly, Bce-like systems have been shown to respond to a large variety of peptide antibiotics that interfere with different stages of cell wall synthesis, including lantibiotics such as nisin, but also the clinically relevant glycopeptides vancomycin and teicoplanin ([@B6], [@B31], [@B32]).

In summary, we report the first observation of transport flux sensing as an elegant way of implementing adaptation via negative feedback regulation. We propose that this represents a highly cost-efficient mode of gene regulation, finely adjusted to the current physiological needs of the cell. In the case of antibiotic resistance mediated by Bce-like systems, this need is an increased demand for detoxification. Future exploration of further systems employing transporters to control a signaling pathway will show if this mechanism can also be found in other physiological contexts.

MATERIALS AND METHODS {#h3}
=====================

Bacterial strains and growth conditions. {#s3.1}
----------------------------------------

All strains used in this study are listed in [Table S3](#tabS3){ref-type="supplementary-material"} in the supplemental material. Strains were routinely propagated in Luria-Bertani (LB) medium. For all functional assays, *B. subtilis* was grown in chemically defined CSE medium ([@B33]), in which the carbon source was modified to provide constant growth rates over an extended period of time \[3.3 g/liter (NH~4~)~2~SO~4~, 29 mM KH~2~PO~4~, 70 mM K~2~HPO~4~, 1× III′ salts (100× III′ salts is 0.232 g/liter MnSO~4~⋅4H~2~O, 12.3 g/liter MgSO~4~⋅7H~2~O), 50 mg/liter tryptophan, 22 mg/liter ammonium ferric citrate, 0.8% (wt/vol) potassium glutamate, 0.6% (wt/vol) sodium succinate, 2.5% (wt/vol) fructose\]. Selective medium for *B. subtilis* contained kanamycin (10 mg/liter), chloramphenicol (5 mg/liter) or erythromycin (1 mg/liter) in combination with lincomycin (25 mg/liter) for macrolide-lincosamide-streptogramin B resistance (MLS^r^). Selective medium for *E. coli* contained ampicillin (100 mg/liter). Solid medium additionally contained 1.5% (wt/vol) agar.

Construction of plasmids and strains. {#s3.2}
-------------------------------------

All cloning was performed according to BioBrick standard RFC10 (<http://hdl.handle.net/1721.1/45138>) or RFC25 (<http://hdl.handle.net/1721.1/45140>). Plasmids, strains, and primer sequences are listed in [Table S3](#tabS3){ref-type="supplementary-material"} in the supplemental material. The *bceAB* operon of *B. subtilis* was adapted to the BioBrick standard by addition of prefix and suffix sequences according to a modified RFC25 standard ([@B22]) using PCR (primers TM2577 and TM2578). All internal PstI sites were changed from CTGCAG to CTCCAG and EcoRI sites from GAATTC to GAGTTC by PCR overlap extension mutagenesis ([@B34]). Point mutations were chosen so to avoid any change in the encoded protein sequence. Cloning of the resulting fragment into the EcoRI and SpeI sites of pSB1A3 resulted in pNTSB103. The P*~xylA~* region of pXT was adapted for BioBrick cloning by the addition of RFC10 prefix and suffix sequences via PCR (primers iGEM134 and iGEM135) and cloning into the EcoRI and SpeI sites of pSB1A3, to generate pNTSB104. Subsequently, the *bceAB* operon was placed under the transcriptional control of P*~xylA~* by BioBrick assembly of the pNTSB103 and pNTSB104 inserts into the vector pBS2E ([@B22]), resulting in pNT2E01. To quantify target promoter activities, wild-type *B. subtilis* W168 was transformed with a transcriptional P*~bceA~*-*luxABCDE* reporter construct, pSDlux101 ([@B35]), producing strain SGB073. Introduction of the same reporter together with pNT2E01 into the *bceAB*::Kan deletion strain TMB035 produced strain SGB218.

Luciferase assays. {#s3.3}
------------------

Luciferase activities were assayed using a Synergy2 multimode microplate reader from BioTek (Winooski, VT) controlled by the software Gen5. Aliquots of culture (100 µl) were added to 96-well plates (black walls, clear bottoms; Greiner Bio-One, Frickenhausen, Germany), which were incubated at 37°C with medium-intensity agitation. Cell growth was monitored by measuring optical density at 600 nm (OD~600~). For each individual sample, the OD~600~ and relative luminescence units (RLU) (endpoint reads; 1-s integration time; sensitivity, 200) were background corrected by subtracting the respective values measured for wells containing 100 µl of CSE medium. RLU/OD~600~ values were calculated for individual measurements. Means and standard deviations of RLU/OD~600~ values were determined from at least three biological replicates.

To synchronize cultures, 10 ml of CSE medium in a 125-ml flask was inoculated with 0.2 ml of an overnight culture and incubated at 37°C with agitation (200 rpm) to an OD~600~ of 0.2 to 0.5. Cultures were then diluted in fresh CSE medium to an OD~600~ of 0.05 and transferred to 96-well plates. OD~600~ and luminescence were monitored every 10 min, and at an OD~600~ of \~0.1 (corresponding to an OD~600~ of \~0.4 in cuvettes with a 1-cm light path length), 5 µl of Zn^2+^ bacitracin was added to give the final concentrations indicated in the figure legends. Incubation was continued, and OD~600~ and luminescence were monitored every 5 min for 1 h. For controlled expression of *bceAB* in strain SGB218, xylose was added to all growth media at the final concentrations indicated in the figure legends.

Bacitracin sensitivity assays. {#s3.4}
------------------------------

The MIC of bacitracin for *B. subtilis* grown in CSE medium was determined by a broth dilution technique. Cultures were grown to stationary phase in CSE medium and then diluted (1:500) into fresh CSE medium containing different concentrations of Zn^2+^ bacitracin. Following 20 to 24 h of incubation at 37°C with agitation, the MIC was scored as the lowest concentration at which no growth was observed. Inhibition of growing cultures ([Fig. 4b](#fig4){ref-type="fig"}) was determined as follows. Cells of strain SGB218 were cultured with the indicated xylose concentrations and challenged with the final concentrations of Zn^2+^ bacitracin indicated in the figure legends as described for the luciferase assays above. Average growth rates (γ) were estimated from an exponential fit to the growth curve (OD~600~) from 0 h (bacitracin addition) to 1 h for each experimental condition. Growth inhibition was calculated as 1 − (γ/γ~max~), where γ~max~ is the maximal growth rate at a given xylose concentration.

Mathematical model and parameter estimation. {#s3.5}
--------------------------------------------

The minimal model for the dynamics of the *bceAB* operon in the wild-type strain SGB073 is described by [equations 1](#eqn1){ref-type="disp-formula"} to 3. In constructing this model we made the simplifying assumption that the maximal amount of UPP in a cell, UPP~tot~, is given by the sum of all intermediate forms of the lipid carrier molecule present in the cell (see [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material for parameter values). Binding of bacitracin to UPP then leads to the accumulation of the bacitracin-bound form of UPP, UPP-bac, to the maximal amount (UPP~tot~). To model the constitutive expression of *bceAB* in strain SGB218, the flux-dependent transcription rate in equation 2 was replaced by a temporally constant transcription rate, which is determined solely by the concentration of externally supplied xylose:
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The xylose-dependent rate of *bceAB* transcription driven by P*~xylA~* was modeled as α~*xyl*~ = α × *f*(*xyl*)/*g*(bac=0), where α is the rate of P*~bceA~*-controlled transcription in the absence of bacitracin and *f*(*xyl*) and *g*(bac) are the experimental dose-response curves for P*~xylA~* ([Fig. 3b](#fig3){ref-type="fig"}) and P*~bceA~* ([Fig. 2B](#fig2){ref-type="fig"}), respectively. In addition, expression of the *luxABCDE* reporter genes in all strains is under the control of an ectopically integrated P*~bceA~* promoter, which is assumed to follow the same transcriptional kinetics as the promoter at its native genomic locus (cf. [equation 2)](#eqn2){ref-type="disp-formula"}:
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Here, *m~lux~* is the *luxABCDE* mRNA, λ~*lux*~ is the associated degradation rate, and all other parameters are the same as in [equation 2](#eqn2){ref-type="disp-formula"}. Assuming that one of the proteins in the *lux* operon is rate limiting for light production, its dynamics is modeled by
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where β is the translation rate and δ~*lux*~ is the corresponding protein half-life. In addition, a multiplicative scaling factor, σ, was introduced to relate the Lux protein level to the experimentally measured luminescence output.

To fit the model to our experimental data, the parameters were fixed to physiological values whenever possible (see [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material) and constrained to physiologically reasonable intervals in all other cases (see [Table S2](#tabS2){ref-type="supplementary-material"} in the supplemental material). Then, a trust region-reflective Newton method (MatLab; The MathWorks, Inc.) was used to minimize the value of χ^2^ between the dose-response curve in [Fig. 2B](#fig2){ref-type="fig"} and the model. To account for the presence of local optima and to quantify the uncertainty in the estimated parameters, 100 independent fits were performed with randomly chosen initial parameter sets (see [Fig. S4 and S5](#figS4 figS5){ref-type="supplementary-material"} in the supplemental material for correlation graphs between χ^2^ and estimated parameters). Confidence intervals for the fitted parameters (see [Table S2](#tabS2){ref-type="supplementary-material"}) were obtained as previously described ([@B36]). The prediction of the dose-response curves for strain SGB218 was based on the parameter set from strain SGB073, but calculated using [equation 4](#eqn4){ref-type="disp-formula"} instead of [equation 2](#eqn2){ref-type="disp-formula"}.

SUPPLEMENTAL MATERIAL {#sm1}
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###### 

Growth curves of strain SGB073 during luciferase assays when challenged with the indicated bacitracin concentrations at 0 min. Download

###### 

Figure S1, EPS file, 0.5 MB

###### 

Activity of P~*bceR*~ in the presence and absence of bacitracin. A strain of *B. subtilis* harboring a transcriptional fusion of the promoter of the BceRS two-component system operon, P~*bceR*~, with the *luxABCDE* reporter of vector pAH328 was grown to mid-exponential phase and then challenged with different concentrations of bacitracin as indicated. Promoter activities were measured as luminescence, corrected for optical density (RLU/OD), over 120 min after bacitracin addition. Results are means ± standard deviations from four independent experiments. Download

###### 

Figure S2, EPS file, 0.1 MB

###### 

Influence of BceS overexpression on bacitracin resistance mediated by BceAB. (A) The negative-control strain TMB1461, carrying a markerless deletion of *bceRSAB*, has an MIC of 1.5 to 2 µg/ml bacitracin, whereas the positive-control strain TMB3097, expressing *bceAB* from the constitutive P~*bceR*~ promoter (medium strength), has an MIC of 4 to 6 µg/ml bacitracin. (C) Expressing of *bceS* from the P*~xylA~* promoter at a promoter strength similar to that of the P~*bceR*~ promoter (strain TMB3095 without xylose; see reference [@B22] for quantitative characteristics of the P*~xylA~* promoter) does not change the MIC compared to the positive control in panel B. (D) Only when *bceS* is expressed 30-fold more strongly than *bceAB* (TMB3095 + 0.02% xylose) is the MIC slightly reduced to 3 to 4 µg/ml, which is still significantly higher than the MIC of the negative-control strain in panel A. These results show that BceAB mediates resistance even if the kinase BceS is overproduced, indicating that the transport activity of BceAB is not restricted through sensory complex formation with BceS *in vivo.* MICs were determined using Etest strips (bioMérieux) according to the manufacturer's instructions. Download
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Figure S3, TIF file, 2.3 MB

###### 

Correlations between the goodness of fit and the estimated parameters. The points correspond to local optima in the parameter space, for which the difference between the quantitative model and the experimental data in [Fig. 2B](#fig2){ref-type="fig"} of the main text is minimal. As the fit quality increases (lower χ^2^), most parameters are confined to narrow intervals, indicating that their values are well constrained by the experimental data. However, some parameters display significant variation even for the lowest χ^2^ values, and one finds, from parameter-parameter correlation analysis in [Fig. S5](#figS5){ref-type="supplementary-material"}, that only combinations of those are well confined by the experimental data. Download

###### 

Figure S4, EPS file, 0.8 MB

###### 

Pairwise scatter plots of individual fit parameters of [Fig. S4](#figS4){ref-type="supplementary-material"} against each other. The correlations between individual fit parameters indicate that only combinations, not individual values of the parameters, are well constrained by the experimental data. Download
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Figure S5, EPS file, 2 MB

###### 

Fixed parameters used in the mathematical model.
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Table S1, DOCX file, 0.1 MB

###### 

Estimated model parameters.

###### 

Table S2, DOCX file, 0.1 MB

###### 

Plasmids, strains and primers used in this study.

###### 

Table S3, DOCX file, 0.02 MB
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